HomeAI · summaries
Storia in 8 fonti
Peptide adcomm Day 2: Emideltide voted down in panel's 1st pushback
As outside experts gathered for a second day to discuss adding certain popular-yet-unapproved peptides to the U.S.’ bulk compounding list, the first to go up against a vote did not fare as well as | As outside experts gathered for a second day to discuss adding certain popular-yet-unapproved peptides to the U.S.’ bulk compounding list, the first to go up against a vote did not fare as well as those assessed Thursday.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
statnews.com
FDA staff and peptide enthusiasts set to clash at advisory panel
FDA advisers are set to consider whether allowing compounding pharmacies to offer largely unproven peptides is a safer bet than the gray-market versions now in use.
- ·
FDA panel confronting peptide controversy
Today's biotech news features the FDA weighing the fate of peptides; approvals for RevMed, GSK; and data on Lilly's "triple-G."
